BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 15519656)

  • 1. Involvement of c-Myc in growth inhibition of Hep 3B human hepatoma cells by a vitamin K analog.
    Ge L; Wang Z; Wang M; Kar S; Carr BI
    J Hepatol; 2004 Nov; 41(5):823-9. PubMed ID: 15519656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylation regulates Myc expression via prolonged activation of the mitogen-activated protein kinase pathway.
    Wang Z; Ge L; Wang M; Carr BI
    J Cell Physiol; 2006 Jul; 208(1):133-40. PubMed ID: 16596619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocyte growth factor enhances protein phosphatase Cdc25A inhibitor compound 5-induced hepatoma cell growth inhibition via Akt-mediated MAPK pathway.
    Wang Z; Wang M; Carr BI
    J Cell Physiol; 2005 Jun; 203(3):510-9. PubMed ID: 15534860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. K vitamins, PTP antagonism, and cell growth arrest.
    Carr BI; Wang Z; Kar S
    J Cell Physiol; 2002 Dec; 193(3):263-74. PubMed ID: 12384979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor cell growth inhibition and extracellular signal-regulated kinase (ERK) phosphorylation by novel K vitamins.
    Osada S; Osada K; Carr BI
    J Mol Biol; 2001 Dec; 314(4):765-72. PubMed ID: 11733995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
    Marampon F; Ciccarelli C; Zani BM
    Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cdc25A and ERK interaction: EGFR-independent ERK activation by a protein phosphatase Cdc25A inhibitor, compound 5.
    Wang Z; Zhang B; Wang M; Carr BI
    J Cell Physiol; 2005 Aug; 204(2):437-44. PubMed ID: 15672448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of Cdc25A phosphatase in Hep3B hepatoma cell growth inhibition induced by novel K vitamin analogs.
    Wang Z; Southwick EC; Wang M; Kar S; Rosi KS; Wilcox CS; Lazo JS; Carr BI
    Cancer Res; 2001 Oct; 61(19):7211-6. PubMed ID: 11585757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue.
    Tamura K; Southwick EC; Kerns J; Rosi K; Carr BI; Wilcox C; Lazo JS
    Cancer Res; 2000 Mar; 60(5):1317-25. PubMed ID: 10728693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Grb2-associated binder-1 plays a central role in the hepatocyte growth factor enhancement of hepatoma growth inhibition by K vitamin analog compound 5.
    Wang Z; Ge L; Wang M; Carr BI
    Hepatology; 2007 Dec; 46(6):2003-13. PubMed ID: 18046719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorinated Cpd 5, a pure arylating K-vitamin derivative, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating MAPK.
    Kar S; Wang M; Ham SW; Carr BI
    Biochem Pharmacol; 2006 Nov; 72(10):1217-27. PubMed ID: 16930563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of rat liver regeneration after partial hepatectomy and induction of ERK phosphorylation by Cpd 5, a K vitamin-based anticancer compound.
    Kar S; Wang M; Rosi KS; Wilcox CS; Carr BI
    Carcinogenesis; 2004 Dec; 25(12):2345-51. PubMed ID: 15319298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Id1 is down-regulated by hepatocyte growth factor via ERK-dependent and ERK-independent signaling pathways, leading to increased expression of p16INK4a in hepatoma cells.
    Ushio K; Hashimoto T; Kitamura N; Tanaka T
    Mol Cancer Res; 2009 Jul; 7(7):1179-88. PubMed ID: 19567783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth inhibition and protein tyrosine phosphorylation in MCF 7 breast cancer cells by a novel K vitamin.
    Kar S; Carr BI
    J Cell Physiol; 2000 Dec; 185(3):386-93. PubMed ID: 11056008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of Ras/Raf-1/ERK actions in the magnolol-induced upregulation of p21 and cell-cycle arrest in colon cancer cells.
    Hsu YF; Lee TS; Lin SY; Hsu SP; Juan SH; Hsu YH; Zhong WB; Lee WS
    Mol Carcinog; 2007 Apr; 46(4):275-83. PubMed ID: 17295239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tumor suppressor KLF11 mediates a novel mechanism in transforming growth factor beta-induced growth inhibition that is inactivated in pancreatic cancer.
    Buck A; Buchholz M; Wagner M; Adler G; Gress T; Ellenrieder V
    Mol Cancer Res; 2006 Nov; 4(11):861-72. PubMed ID: 17114344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanism of cell cycle blockage of hepatoma SK-Hep-1 cells by Epimedin C through suppression of mitogen-activated protein kinase activation and increased expression of CDK inhibitors p21(Cip1) and p27(Kip1).
    Liu TZ; Chen CY; Yiin SJ; Chen CH; Cheng JT; Shih MK; Wang YS; Chern CL
    Food Chem Toxicol; 2006 Feb; 44(2):227-35. PubMed ID: 16112786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-21-activated protein kinase-1 functions as a linker between insulin and Wnt signaling pathways in the intestine.
    Sun J; Khalid S; Rozakis-Adcock M; Fantus IG; Jin T
    Oncogene; 2009 Sep; 28(35):3132-44. PubMed ID: 19581924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dependence of EGF-induced increases in corneal epithelial proliferation and migration on GSK-3 inactivation.
    Wang Z; Yang H; Zhang F; Pan Z; CapĆ³-Aponte J; Reinach PS
    Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4828-35. PubMed ID: 19443725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.